Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations
Top Cited Papers
Open Access
- 1 May 2014
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (5), 1712-1721
- https://doi.org/10.1210/jc.2013-3059
Abstract
Context: Measurement of IGF-I is a cornerstone in diagnosis and monitoring of GH-related diseases, but considerable discrepancies exist between analytical methods. A recent consensus conference defined criteria for validation of IGF-I assays and for establishment of normative data. Objectives: Our objectives were development and validation of a novel automated IGF-I immunoassay (iSYS; Immunodiagnostic Systems) according to international guidelines and establishment of method-specific age- and sex-adjusted reference intervals and analysis of their robustness. Setting and Participants: We conducted a multicenter study with samples from 12 cohorts from the United States, Canada, and Europe including 15 014 subjects (6697 males and 8317 females, 0–94 years of age). Main Outcome Measures: We measured concentrations of IGF-I as determined by the IDS iSYS IGF-I assay. Results: A new IGF-I assay calibrated against the recommended standard (02/254) and insensitive to the 6 high-affinity IGF binding proteins was developed and rigorously validated. Age- and sex-adjusted reference intervals derived from a uniquely large cohort reflect the age-related pattern of IGF-I secretion: a decline immediately after birth followed by an increase until a pubertal peak (at 15 years of age). Later in life, values decrease continuously. The impact of gender is small, although across the lifespan, women have lower mean IGF-I concentrations. Geographical region, sampling setting (community or hospital based), and rigor of exclusion criteria in our large cohort did not affect the reference intervals. Conclusions: Using large cohorts of well-characterized subjects from different centers allowed construction of robust reference ranges for a new automated IGF-I assay. The strict adherence to recent consensus criteria for IGF-I assays might facilitate clinical application of the results.Keywords
This publication has 37 references indexed in Scilit:
- The Association Between IGF-I and Insulin ResistanceDiabetes Care, 2012
- Annual Change in Insulin SensitivityHormone and Metabolic Research, 2011
- A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3Human Molecular Genetics, 2011
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- Cohort Profile: The Study of Health in PomeraniaInternational Journal of Epidemiology, 2010
- Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adultsGrowth Hormone & IGF Research, 2009
- Longitudinal Analysis of the Insulin-Like Growth Factor System in African-American and European American Children and AdolescentsJournal of Clinical Endocrinology & Metabolism, 2008
- Reference levels for 17-hydroxyprogesterone, 11-desoxycortisol, cortisol, testosterone, dehydroepiandrosterone sulfate and androstenedione in infants from birth to six months of ageEuropean Journal of Pediatrics, 2007
- Blood pressure centiles for Great BritainArchives of Disease in Childhood, 2006
- Smoothing reference centile curves: The lms method and penalized likelihoodStatistics in Medicine, 1992